06MA Stock Chart & Stats
€5.55
€0.00(0.00%)
At close: 4:00 PM EDT
€5.55
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.10 - €6.35
Previous CloseN/A
Volume0.00
Average Volume (3M)27.00
Market Cap
€325.12M
Enterprise Value€206.79
Total Cash (Recent Filing)€132.95M
Total Debt (Recent Filing)€60.13M
Price to Earnings (P/E)31.4
Beta0.87
Next Earnings
Aug 27, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding59,067,184
10 Day Avg. Volume42
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)1.09
Price to Sales (P/S)1.09
P/FCF Ratio30.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.02Price Target Upside26.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.16
Revenue Forecast (FY)€240.45M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthMaterialise's net cash position (~EUR72.8m) and sizable cash reserves with modest gross debt provide durable financial flexibility. This low leverage supports continued investment in software and medical R&D, capex for manufacturing, opportunistic M&A or buybacks, and cushions demand shocks over the medium term.
High Recurring Software RevenueSoftware revenue with ~83% recurring mix and sharply improved software EBITDA shows a shift toward annuity-like income and operating leverage. As customers migrate to cloud/subscription, predictable cash flows, higher margins and stronger customer retention should stabilize revenue and profitability over multiple quarters.
Medical Segment Momentum & New ProductsMedical growth and clinical product launches expand addressable markets and deepen clinical integration. Patient-specific implants and advanced planning tools create higher switching costs, tie revenue to procedure volumes and reimbursement flows, and typically deliver more durable, higher-margin revenue than one-off prototyping.
Bears Say
Manufacturing Revenue WeaknessThe manufacturing/services business is volumetric and cyclical; an 8% YoY decline driven by weak prototyping and automotive demand signals utilization and pricing pressure. Prolonged end-market softness can depress revenue and manufacturing margins, underutilize capital equipment and constrain cash generation over several quarters.
Volatile Free Cash Flow And Weak Cash ConversionSmall, volatile free cash flow and weak conversion (~31% of net income TTM) limit the company's ability to sustainably fund reinvestment, acquisitions or returns to shareholders. Intermittent negative FCF historically increases dependence on reserves and raises execution risk for strategic investments over the medium term.
Material FX SensitivityNotable currency translation headwinds reduce reported revenue and mask underlying operational growth. Persistent FX volatility complicates multi‑period visibility, budgeting and performance comparisons, and can depress reported margins even if volumes hold, creating recurring noise in financial results.
Materialise News
06MA FAQ
What was Materialise NV’s price range in the past 12 months?
Materialise NV lowest stock price was €4.10 and its highest was €6.35 in the past 12 months.
What is Materialise NV’s market cap?
Materialise NV’s market cap is €325.12M.
When is Materialise NV’s upcoming earnings report date?
Materialise NV’s upcoming earnings report date is Aug 27, 2026 which is in 24 days.
How were Materialise NV’s earnings last quarter?
Materialise NV released its earnings results on May 07, 2026. The company reported €0.03 earnings per share for the quarter, beating the consensus estimate of €0.01 by €0.02.
Is Materialise NV overvalued?
According to Wall Street analysts Materialise NV’s price is currently Undervalued.
Does Materialise NV pay dividends?
Materialise NV does not currently pay dividends.
What is Materialise NV’s EPS estimate?
Materialise NV’s EPS estimate is 0.04.
How many shares outstanding does Materialise NV have?
Materialise NV has 59,067,184 shares outstanding.
What happened to Materialise NV’s price movement after its last earnings report?
Materialise NV reported an EPS of €0.03 in its last earnings report, beating expectations of €0.01. Following the earnings report the stock price went down -0.844%.
Which hedge fund is a major shareholder of Materialise NV?
Currently, no hedge funds are holding shares in DE:06MA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Materialise Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.02 (26.51% Upside)
€7.02 (26.51% Upside)
Blogger Sentiment
Bullish
DE:06MA Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.33%
Trailing 12-Months
Company Description
Materialise NV
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
06MA Company Deck
06MA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial picture: revenue was stable despite FX headwinds, margins and adjusted profitability improved materially (adjusted EBITDA +>30%, adjusted EBIT up meaningfully), Medical reported solid growth with strategic product launches, software recurring revenue increased and software profitability improved, cash position strengthened, and sustainability and strategic portfolio actions were executed. Offsetting factors include FX-driven reported declines in some areas, an 8% YoY drop in Manufacturing revenue driven by softer prototyping and automotive demand, and the near‑term top‑line impact of divestments. On balance, the favorable profitability trends, cash generation, product and partnership momentum, and reaffirmed guidance outweigh the lowlights.View all DE:06MA earnings summaries06MA Stock 12 Month Forecast
Average Price Target
€7.02
▲(26.51% Upside)